Founded in 2017, Khiron Life Sciences is striving to improve the quality of life for patients in Latin America and Europe through medical cannabis. Unlike more established US states, their markets are in the earlier innings. Cannabis is prescribed by doctors, filled by pharmacists, and the product types are much more limited. Even with these constraints, they are having great success in building the patient base, driving revenues, and improving people's lives.
CEO Alvaro Torres joined us on Seeking Alpha to discuss the origins of the business, and how cannabis is being adopted in their core Latin America and European markets. My favorite segment was talking about how they are transitioning from treating chronic pain with cannabis versus opioids. This hits home with me, as my dad is having great results using cannabis for his Chronic Regional Pain Syndrome. Khiron is seeing similar outcomes.
We closed the conversation covering opportunities in Europe and Alvaro's predictions for 2022 and into 2023. For investors seeking exposure to emerging international cannabis markets, Khiron is an excellent consideration. They trade on the US OTC Exchange under KHRNF and are even positive year-to-date.
Here's a link to the full interview: https://seekingalpha.com/article/4504201-medical-cannabis-in-latin-america-khiron-ceo-alvaro-torres